Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.

Strohbehn GW, Ratain MJ.

Clin Pharmacol Ther. 2019 Sep;106(3):498-500. doi: 10.1002/cpt.1428. Epub 2019 Apr 5. No abstract available.

PMID:
30951196
2.

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Leone RD, Lo YC, Powell JD.

Comput Struct Biotechnol J. 2015 Apr 8;13:265-72. doi: 10.1016/j.csbj.2015.03.008. eCollection 2015. Review.

3.

Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists.

van der Walt MM, Terre'Blanche G.

Bioorg Chem. 2018 Apr;77:136-143. doi: 10.1016/j.bioorg.2018.01.004. Epub 2018 Jan 4.

PMID:
29353730
4.

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.

Leone RD, Sun IM, Oh MH, Sun IH, Wen J, Englert J, Powell JD.

Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284. doi: 10.1007/s00262-018-2186-0. Epub 2018 Jun 19.

PMID:
29923026
5.

Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.

van Waarde A, Dierckx RAJO, Zhou X, Khanapur S, Tsukada H, Ishiwata K, Luurtsema G, de Vries EFJ, Elsinga PH.

Med Res Rev. 2018 Jan;38(1):5-56. doi: 10.1002/med.21432. Epub 2017 Jan 27. Review.

PMID:
28128443
6.

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.

Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD.

Cancer Immunol Immunother. 2012 Jun;61(6):917-26. doi: 10.1007/s00262-011-1155-7. Epub 2011 Nov 25.

7.

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. doi: 10.1073/pnas.1308209110. Epub 2013 Aug 20.

8.

Protein kinase C regulates adenosine A2a receptor mRNA expression in SH-SY5Y cells.

Peterfreund RA, Gies EK, Fink JS.

Eur J Pharmacol. 1997 Oct 1;336(1):71-80.

PMID:
9384256
9.

Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice.

Belikoff B, Hatfield S, Sitkovsky M, Remick DG.

Shock. 2011 Apr;35(4):382-7. doi: 10.1097/SHK.0b013e3182085f12.

10.

Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors.

Legoabe LJ, Van der Walt MM, Terre'Blanche G.

Chem Biol Drug Des. 2018 Jan;91(1):234-244. doi: 10.1111/cbdd.13074. Epub 2017 Aug 16.

PMID:
28734058
11.

A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update.

Guerrero A.

Curr Med Chem. 2018;25(30):3597-3612. doi: 10.2174/0929867325666180313110254. Review.

PMID:
29532748
12.

5-Substituted 2-benzylidene-1-tetralone analogues as A1 and/or A2A antagonists for the potential treatment of neurological conditions.

Janse van Rensburg HD, Terre'Blanche G, van der Walt MM, Legoabe LJ.

Bioorg Chem. 2017 Oct;74:251-259. doi: 10.1016/j.bioorg.2017.08.013. Epub 2017 Aug 30.

PMID:
28881253
13.

Adenosine A2A receptor agonists with potent antiplatelet activity.

Fuentes E, Fuentes M, Caballero J, Palomo I, Hinz S, El-Tayeb A, Müller CE.

Platelets. 2018 May;29(3):292-300. doi: 10.1080/09537104.2017.1306043. Epub 2017 May 15.

PMID:
28504052
14.

Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists.

Harmse R, van der Walt MM, Petzer JP, Terre'Blanche G.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5951-5955. doi: 10.1016/j.bmcl.2016.10.086. Epub 2016 Oct 31.

PMID:
27836398
15.

Mechanisms of the adenosine A2A receptor-induced sensitization of esophageal C fibers.

Brozmanova M, Mazurova L, Ru F, Tatar M, Hu Y, Yu S, Kollarik M.

Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G215-23. doi: 10.1152/ajpgi.00350.2014. Epub 2015 Nov 12.

16.

Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors.

Chiodi V, Ferrante A, Ferraro L, Potenza RL, Armida M, Beggiato S, Pèzzola A, Bader M, Fuxe K, Popoli P, Domenici MR.

J Neurochem. 2016 Mar;136(5):907-17. doi: 10.1111/jnc.13421. Epub 2015 Nov 24.

17.

Adenosine A2A receptor induces protein kinase A-dependent functional modulation of human (alpha)3(beta)4 nicotinic receptor.

Di Angelantonio S, Piccioni A, Moriconi C, Trettel F, Cristalli G, Grassi F, Limatola C.

J Physiol. 2011 Jun 1;589(Pt 11):2755-66. doi: 10.1113/jphysiol.2011.207282. Epub 2011 Apr 11.

18.

Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects.

Paterniti I, Melani A, Cipriani S, Corti F, Mello T, Mazzon E, Esposito E, Bramanti P, Cuzzocrea S, Pedata F.

J Neuroinflammation. 2011 Apr 12;8:31. doi: 10.1186/1742-2094-8-31.

19.

Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion.

Gazoni LM, Laubach VE, Mulloy DP, Bellizzi A, Unger EB, Linden J, Ellman PI, Lisle TC, Kron IL.

J Thorac Cardiovasc Surg. 2008 Jan;135(1):156-65. doi: 10.1016/j.jtcvs.2007.08.041. Epub 2007 Nov 26.

20.

Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes.

Sun WC, Moore JN, Hurley DJ, Vandenplas ML, Linden J, Cao Z, Murray TF.

Vet Immunol Immunopathol. 2008 Jan 15;121(1-2):91-100. Epub 2007 Aug 25.

PMID:
17913243

Supplemental Content

Support Center